comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 23:03:12 - browse：166

Adam's take main illustration — Molly Ferguson/STAT

I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

Do you have a biotech-related question you want me to answer in the newsletter? Send me an email at [email protected].

This week: A preview of Intra-Cellular Therapies’ Phase 3 study in major depressive disorder, and a couple of liver-disease physician perspectives on Rezdiffra, the newly approved treatment for MASH from Madrigal Pharmaceuticals.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Trans patients at the end of life deserve respect and dignity

WSS

Wegovy improves function in certain heart failure patients

Researchers CRISPR chickens in bid to protect them from bird flu

Life sciences deals on track to hit lowest point since 2017

California store owner shot dead in dispute over displaying Pride flag: Police

Roche's accidental data boosts hopes for anti

National associations that represent hospice owe an apology

explore

comprehensive

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Wildfire smoke exposes gaps in outdoor worker protections

Trans patients at the end of life deserve respect and dignity

Medicare details structure of new drug price negotiation program

PBMs are inflating the cost of generic drugs. They must be reined in

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Humana CEO Bruce Broussard to step down in 2024

Cancer drug shortages should be causing more outrage

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

hotspot

Meadows told special counsel he could not recall Trump ever declassifying Mar

Wellcome Trust names Røttingen as its new CEO

Wellcome Trust names Røttingen as its new CEO

National associations that represent hospice owe an apology

STAT Readout: Today's biotech news includes Sana and Amylyx

Akero's treatment for NASH falls short in cirrhosis study

hotspot

focus

knowledge

entertainment